Clinical Trial Update: A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) [Phase 3]

View source ↗

Summary

A Phase 3 trial (SIMRISE) is evaluating SIM0270 in combination with everolimus versus physician's choice in ER+/HER2- advanced/metastatic breast cancer; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• SIM0270 (SIM0270)

Snippet

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Conditions: Locally Advanced or Metastatic Breast Cancer | Phase 3 | Status: RECRUITING